Endocrine Abstracts

Background: Dulaglutide has been approved as a hypoglycemic agent for the treatment of patients with T2DM. A positive effect on carbohydrate metabolism and body weight was shown in RCT.It was found that GLP-1 agonists may prevent the progression of NAFLD directly affecting lipid metabolism and inflammation.Aim: To assess the effect of dulaglutide on carbohydrate and hepatic metabolism in patients with T2DM and NAFLD in real clinica...

Aim: To estimate the frequency of changes in thyroid function on the background of antiviral therapy in patients with chronic hepatitis C.Material and methods: The retrospective group was consists of 204 patients (mean age 35.5±8.4 years) with HCV genotype 3a, who took the antiviral therapy course with pegylated interferon and ribavirin during 24 weeks. The patients were divided for two groups: 86.3% (176) had a sustained virological response (SVR),...